Artiva (ARTV) CEO Fred Aslan Receives 200,000-Share Award

What Happened

• Fred Aslan, CEO of Artiva Biotherapeutics (ARTV), received equity awards on 2026-09-10: 45,000 restricted stock units (RSUs) and 155,000 derivative option-style awards. Both grants show an acquisition price of $0.00 (standard compensation grants), totaling 200,000 potential shares. This is an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-10; filing date: 2026-09-14 (Form 4 filed within the 2 business‑day deadline — timely).
• Prices: $0.00 for both grants (no cash paid by the insider).
• Shares reported acquired: 45,000 (RSU) + 155,000 (derivative) = 200,000 total.
• Shares owned after transaction: Not specified in the reported details (the Form 4 did not list total company holdings after these grants).
• Footnotes: F1 — 45,000 RSUs granted under the Issuer’s 2024 Equity Incentive Plan. F2 — the 155,000 derivative award is subject to vesting: beginning Sept 8, 2026, 1/48th vests monthly over four years (typical multi-year vesting schedule).
• Transaction code: A = Award/Grant.

Context

• RSUs and option-style derivative awards are compensation and generally vest over time; they do not represent an immediate market purchase or sale. The 155,000-unit derivative award will vest gradually (1/48th per month) starting Sept 8, 2026, before becoming owned shares or exercisable instruments. Such grants are common for executives as long-term incentive pay and should not be read as an immediate buying or selling signal.